

A²

10. (amended) The method of claim 9 wherein the modulator is salicylihalamide A.

A³

15. (amended) A method of promoting cell death following exposure to irradiation comprising contacting said cell with an agent capable of inhibiting acidic vesicular function or acidification.

A⁴

17. (amended) The method of claim 13 wherein the agent is a macrolide.

A⁵

21. (amended) The method of claim 20 wherein the agent is salicylihalamide A.

REMARKS

Claims 1-21 are currently pending in the application. Claims 10, 17 and 21 are objected to; Claims 2, 15 and 21 are rejected under 35 U.S.C. §112, second paragraph; and claims 1, 4-14, 16-21 are rejected under 35 U.S.C. §103 (a). For reasons detailed below, the rejections should be withdrawn and the claims allowed to issue. Entry of the foregoing amendments is respectfully requested.

1. Claim Objections

The Examiner has objected to claims 10, 17 and 21. According to the Examiner, claims 10 and 21 misspell the word salicylihalamide A. In addition, the word "an macrolide" in claim 17 appears to be a typographical error.